NCT01286909View on ClinicalTrials.gov

Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)

PHASE3UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Metabolic Disease
Interventions
DIETARY_SUPPLEMENT

LaFlavon

two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months

Trial Locations (1)

Unknown

RECRUITING

Rafic Hariri University Hospital, Beirut

Sponsors
All Listed Sponsors
lead

Omicron Pharmaceuticals

INDUSTRY

NCT01286909 - Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL) | Biotech Hunter | Biotech Hunter